In a recent publication in Viruses, Dr. Ishac Nazy from McMaster University finds that SARS-CoV-2 antibodies against the spike and receptor binding domain are present for at least six months, confirming similar research by other CITF-funded researchers. In this publication, Dr. Nazy characterizes SARS-CoV-2 antibodies in recovered COVID-19 patients. This study was funded in [...]
In a publication in the Journal of Clinical Investigation, Drs. Daniel Kaufmann and Andrés Finzi from Université de Montréal and collaborators, found that patients with acute SARS-CoV-2 infection have altered immune responses affecting the severity of symptoms and mortality. These findings may help clinicians identify patients at risk of unfavourable outcomes and shed light [...]
The 20 Most-Read Articles in March 2021 Their article was read over 1300 times in the last 5 months While many agree on the importance of antibodies in SARS-CoV-2 infection, T cells have also taken the spotlight as a key contributor to immunity. Published in The Journal of Immunology, Drs. Tania Watts and [...]
Immune cell analysis reveals that the amount of SARS-CoV-2 in the blood is a strong predictor of mortality
As SARS-CoV-2 continues to cause worldwide mortality, it has become increasingly important to define molecular markers that can identify individuals at risk of developing severe COVID-19, and even death. This could help in determining early preventive measures for improved patient outcomes. In a recent pre-print and therefore not yet peer-reviewed, CITF-funded researchers Drs. Daniel [...]
Using a glowing SARS-CoV-2 virus and mice to explain how antibodies protect from infection and severe disease
An international multisite research collaboration, including CITF-funded researcher Dr. Andrés Finzi from the Université de Montréal, used genetically modified mice that mimic COVID-19 disease in humans to study how antibodies from people who have recovered from COVID-19 could prevent severe disease in other people. The authors concluded that these antibodies were effective in not [...]
Why do some people experience mild COVID-19 symptoms and others have severe illness? Pre-existing antibodies could explain the range of COVID-19 illness
CITF-funded researcher Dr. Pascal Lavoie from the University of British Columbia and his collaborators are suggesting that the presence of antibodies to SARS-CoV-2 may not necessarily indicate a previous infection. Using highly sensitive tests, they discovered pre-existing antibodies to SARS-CoV-2 in many uninfected adults. The study was funded in part by the COVID-19 Immunity [...]
Dr. Ishac Nazy and the McMaster Platelet Immunology Laboratory have found some of the reasons behind why some patients with severe COVID-19 have blood clots. The team found that blood from critically ill COVID-19 patients contains molecules that can activate cells involved in blood clotting. This study was supported by the Canadian Institutes of [...]
Dr. Andrés Finzi from the Université de Montréal and Dr. Renée Bazin from Héma-Québec and their teams recently describe a novel high-throughput method to track levels of antibodies made against SARS-CoV-2 spike protein in the plasma of donors that recovered from COVID-19 in a recent issue of Transfusion.
Dr. Andrés Finzi, from the Université de Montréal, Dr. Renée Bazin from Héma-Québec, along with collaborators from Western University, are highlighting the importance of antibodies made early on in the infection in SARS-CoV-2 neutralization.
Researchers find cellular immune response to SARS-CoV-2 lasts at least eight months, even after antibodies levels decreased
Researchers from Université de Montréal, Dr Daniel Kaufmann and Dr Andres Finzi, in collaboration with researchers from New York University, are confirming the presence of a long-lasting immune response to the novel coronavirus SARS-CoV-2, in a pre-print publication.